GlassScriptPhysician profile
Helen A Mashek
NPI 1023012515
$8,936.86
in general payments reported to CMS, 2019-2025
32 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $456 · 2021: $760 · 2022: $1,289 · 2023: $1,162 · 2024: $1,695 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,365.59 |
| Education | $375.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,724.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $965.19 | 2019-2025 | |
| Janssen Biotech, INC. | $951.85 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $808.71 | 2019-2025 | |
| Ucb, INC. | $579.98 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $514.50 | 2019-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $384.91 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $378.67 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $330.14 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $297.60 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $291.87 | 2019-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $279.44 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $262.76 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $237.33 | 2019-2025 | Libtayo, Dupixent |
| Amgen INC. | $191.79 | 2021-2025 | Otezla, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $177.89 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.60 | 2019-2025 | Cabtreo, Siliq |
| Celgene Corporation | $106.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.70 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $41.29 | 2019-2022 | |
| Leo Pharma INC. | $33.99 | 2021-2023 | Adbry |
| Epi Health, LLC | $27.99 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.54 | 2024 | Acthar |
| Journey Medical Corporation | $23.95 | 2023 | |
| Paratek Pharmaceuticals, INC. | $22.35 | 2025 | Nuzyra |
| Vyne Pharmaceuticals INC. | $20.13 | 2020 | |
| Krystal Biotech INC | $18.77 | 2024 | Vyjuvek |
| Almirall LLC | $18.33 | 2022 | |
| Dusa Pharmaceuticals, INC. | $16.44 | 2019 | |
| Biofrontera INC. | $16.33 | 2019 | |
| Verrica Pharmaceuticals INC. | $13.22 | 2024 | Ycanth |
| Mission Pharmacal Company | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Mashek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.